Catalyst Wire Dossier Catalyst Wire Dossier

QLC7401

· Qilu Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for QLC7401, covering 2024-12-27 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) [Phase 3]

See pricing